300832 ShenZhen New Industries Biomedical Engineering
- 65.37
- +1.81+2.85%
ShenZhen New Industries Biomedical Engineering News
Shenzhen new industries biomedical engineering (300832.SZ): has obtained the registration certificate for the complement C3 assay kit (immunoturbidimetric method) medical instruments.
Shenzhen New Industries Biomedical Engineering (300832.SZ) announced on November 26th that the company recently received a 'medical instruments registration certificate' issued by the Guangdong Pharmaceutical Supervision Administration. The product is named Complement C3 Assay Kit (immunoturbidimetry), with registration number Yue Equipment Standard 20242401551, valid from November 21, 2024, to November 20, 2029. This assay kit is used for quantitative determination of complement C3 in human serum and plasma, clinically used for auxiliary diagnosis of complement deficiencies or related immunodeficiency diseases. This certification enriches the company's biochemical testing products.
shenzhen new industries biomedical engineering (300832.SZ): Received a medical instruments registration certificate.
Gelonghui reported on November 21 that shenzhen new industries biomedical engineering (300832.SZ) announced that recently, it received a medical instruments registration certificate issued by the Guangdong Provincial Drug Administration. This is for the cyclosporine assay kit (magnetic microparticle chemiluminescence method).
Is Shenzhen New Industries Biomedical Engineering Co., Ltd.'s (SZSE:300832) Stock's Recent Performance A Reflection Of Its Financial Health?
Shenzhen New Industries Biomedical Engineering Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
New Industries: 2024 Third Quarter Report
Shenzhen New Industries Biomedical Engineering (300832.SZ) released its performance for the first three quarters, with a net income of 1.384 billion yuan, an increase of 16.59%.
shenzhen new industries biomedical engineering (300832.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 34...
shenzhen new industries biomedical engineering (300832.SZ): net income of 1.384 billion yuan in the first three quarters, a year-on-year increase of 16.59%.
On October 28th, Guolonghui announced the third quarter report of 2024, with the company achieving a revenue of 3.414 billion yuan in the first three quarters, a year-on-year increase of 17.41%; the net income attributable to shareholders of the listed company was 1.384 billion yuan, a year-on-year increase of 16.59%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.331 billion yuan, a year-on-year increase of 20.80%; and the basic earnings per share was 1.7609 yuan.
Express News | Shenzhen New Industries Q3 Net Profit up 10.0% Y/Y
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 95.79 Yuan From 95.86 Yuan, Keeps at Buy
Shenzhen New Industries Biomedical Engineering (300832.SZ) main shareholder Rao Wei's concerted actor and director Rao Jie completed the shareholding of 0.6 million shares.
Announcement from Shenzhen New Industries Biomedical Engineering (300832.SZ), the company's shareholder with more than 5% holdings, Raowei, a shareholder's person acting in concert and director Rao Jie...
Shenzhen new industries biomedical engineering (300832.SZ) products have obtained IVDR CE certification.
Shenzhen New Industries Biomedical Engineering (300832.SZ) announced that recently, the company has released human immunodeficiency virus antigen and antibody detection reagents...
Guosen Securities: After the centralized procurement of IVD, the industry landscape has changed, and the assembly line has become a battleground.
In the environment of centralized procurement, having TLA products with low cost and high quality will become the core competitiveness of IVD companies.
Is Shenzhen New Industries Biomedical Engineering Co., Ltd. (SZSE:300832) Trading At A 24% Discount?
Shenzhen New Industries Biomedical Engineering (300832.SZ): The 'parathyroid hormone detection reagent kit (chemiluminescent magnetic microparticle method)' obtained the medical instruments registration certificate.
Gelonghui September 6th | Shenzhen New Industries Biomedical Engineering (300832.SZ) announced that recently, Shenzhen New Industries Biomedical Engineering Co., Ltd. received a "Medical Device Registration Certificate" issued by the Guangdong Provincial Administration of Pharmaceutical. For the parathyroid hormone assay kit (magnetic chemiluminescence method).
Shareholders Liu Haiyan and Xu Dinghong collectively reduced their holdings by 0.201 million shares in Shenzhen New Industries Biomedical Engineering (300832.SZ).
Shenzhen New Industries Biomedical Engineering (300832.SZ) announced that the company has received letters from Ms. Xu Dinghong, Ms. Liu Haiyan, and Ms. Zhang Lei...
Sinolink Securities: The large pharmaceutical sector is a key point in the mid-year report, and it is expected to see a overall recovery in the pharmaceutical sector in the second half of the year.
Looking ahead to the second half of the year, with the decline in the base, the recovery of procurement sentiment, and the stabilization of policy expectations, I am bullish on the recovery of demand for pharmaceutical and medical device products within hospitals, as well as the acceleration of performance growth. The pharmaceutical sector is expected to experience an overall reversal in the second half of the year.
Shenzhen New Industries Biomedical Engineering's H1 Profit Jumps 20%, Operating Income Up 19%
ShenZhen New Industries Biomedical Engineering: Summary of Half-Year Report in 2024.
ShenZhen New Industries Biomedical Engineering: Half-year report for the year 2024.
Shenzhen New Industries Biomedical Engineering (300832.SZ): net income in the first half of the year was 0.903 billion yuan, a year-on-year increase of 20.42%.
On August 22, Gelonghui announced its interim report for the first half of 2024, with a revenue of 2.211 billion yuan, an increase of 18.54% compared to the same period last year; a net income of 0.903 billion yuan attributable to shareholders of the listed company, an increase of 20.42% compared to the same period last year; a net income of 0.868 billion yuan attributable to shareholders of the listed company after deducting non-recurring gains and losses, an increase of 26.36% compared to the same period last year; and a basic earnings per share of 1.1495 yuan.
Analysis
Price Target
No Data
No Data